drugset / Trial / NCT07643038
Treatment Strategy for Patients With RA-ILD
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, rituximab, and csDMARD methotrexate in patients with RA-ILD.
Timeline
- Start
- 2026-09-20
- Primary completion
- 2029-07-31
- Completion
- 2029-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methotrexate | Small molecule | 15 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 500 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |